RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+50.37%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.65B
AUM Growth
+$3.65B
(+51%)
Cap. Flow
+$447M
Cap. Flow
% of AUM
12.25%
Top 10 Holdings %
Top 10 Hldgs %
23.51%
Holding
147
New
14
Increased
83
Reduced
11
Closed
4
Top Buys
| 1 |
Novavax
NVAX
|
$47.6M |
| 2 |
Centene
CNC
|
$35.9M |
| 3 |
UnitedHealth
UNH
|
$31M |
| 4 |
Edwards Lifesciences
EW
|
$26.8M |
| 5 |
Royalty Pharma
RPRX
|
$24.3M |
Top Sells
| 1 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
$42.7M |
| 2 |
Intuitive Surgical
ISRG
|
$18.5M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$7.9M |
| 4 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$7.48M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$5.41M |
Sector Composition
| 1 | Healthcare | 92.16% |
| 2 | Consumer Staples | 1.09% |
| 3 | Consumer Discretionary | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$13.8B
| $167M | 4.57% | 1,366,500 +17,000 | +1% | +$2.07M |
|
|
2
UnitedHealth
UNH
$281B
| $119M | 3.28% | 405,000 +105,000 | +35% | +$31M |
|
|
3
Centene
CNC
$14.3B
| $83.6M | 2.29% | 1,315,000 +565,000 | +75% | +$35.9M |
|
4
iRhythm Technologies
IRTC
$5.46B
| $75.4M | 2.07% | 651,000 +6,000 | +0.9% | +$695K |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $74.9M | 2.05% | 960,029 +223,029 | +30% | +$17.4M |
|
6
Humana
HUM
$36.5B
| $74.1M | 2.03% | 191,000 +33,500 | +21% | +$13M |
|
|
7
Intuitive Surgical
ISRG
$170B
| $68.4M | 1.88% | 120,000 -32,500 | -21% | -$18.5M |
|
8
Zai Lab
ZLAB
$3.68B
| $66.8M | 1.83% | 813,246 +63,246 | +8% | +$5.19M |
|
9
argenx
ARGX
$43.6B
| $64.8M | 1.78% | 287,500 +40,000 | +16% | +$9.01M |
|
10
Agios Pharmaceuticals
AGIO
$2.19B
| $63.1M | 1.73% | 1,179,720 +124,220 | +12% | +$6.64M |
|
|
IMMU
11
DELISTED
Immunomedics Inc
IMMU
| $59.5M | 1.63% | 1,677,679 +627,679 | +60% | +$22.2M |
|
12
Insulet
PODD
$23.9B
| $56.9M | 1.56% | 293,000 +1,000 | +0.3% | +$194K |
|
13
Baxter International
BAX
$12.7B
| $55.5M | 1.52% | 645,000 | – | – |
|
14
Sarepta Therapeutics
SRPT
$1.78B
| $55.4M | 1.52% | 345,500 | – | – |
|
15
HCA Healthcare
HCA
$94.5B
| $53.3M | 1.46% | 549,500 +29,500 | +6% | +$2.86M |
|
16
Encompass Health
EHC
$12.3B
| $51.6M | 1.41% | 832,500 +17,500 | +2% | +$1.08M |
|
17
Acadia Pharmaceuticals
ACAD
$4.38B
| $51.1M | 1.4% | 1,055,000 +30,000 | +3% | +$1.45M |
|
|
18
Alnylam Pharmaceuticals
ALNY
$58.5B
| $51.1M | 1.4% | 345,000 -36,500 | -10% | -$5.41M |
|
|
19
Ultragenyx Pharmaceutical
RARE
$2.89B
| $50.6M | 1.39% | 646,841 -100,959 | -14% | -$7.9M |
|
20
Pacira BioSciences
PCRX
$1.2B
| $48.5M | 1.33% | 925,000 +25,000 | +3% | +$1.31M |
|
21
Biogen
BIIB
$19.4B
| $48.2M | 1.32% | 180,000 | – | – |
|
22
BioMarin Pharmaceuticals
BMRN
$11.2B
| $47.8M | 1.31% | 387,500 +7,500 | +2% | +$925K |
|
|
23
Novavax
NVAX
$1.21B
| $47.6M | 1.3% | +570,598 | New | +$47.6M |
|
24
Teleflex
TFX
$5.59B
| $47.3M | 1.3% | 130,000 | – | – |
|
|
NVRO
25
DELISTED
NEVRO CORP.
NVRO
| $46.1M | 1.26% | 386,000 +40,000 | +12% | +$4.78M |
|